# Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

Study · id `cardio:ct-nct02640794` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02640794](<https://clinicaltrials.gov/study/NCT02640794>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02640794

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Valve and congenital heart disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.

## Technical summary

Registry record NCT02640794. Randomized; no masking; primary purpose prevention. Start 2015-01 (actual); primary completion 2017-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 222 participants (enrolled count; ClinicalTrials.gov record NCT02640794, source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)
- Started: 2015-01 (actual) (ClinicalTrials.gov record NCT02640794, source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)
- Primary completion: 2017-06 (actual) (ClinicalTrials.gov record NCT02640794, source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)
- Completion: 2018-03 (actual) (ClinicalTrials.gov record NCT02640794, source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)
- Countries: Canada; Chile; Spain (ClinicalTrials.gov record NCT02640794, source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02640794-2018-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI
- Acronym: ARTE
- Condition: Aortic Valve Disease
- Condition: Myocardial Infarction
- Condition: Stroke
- Condition: Bleeding
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Aspirin
- Lead sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (`cardio:org-centre-de-recherche-de-l-institut-universitaire-de-17cd1e`)

## Provenance

Content hash: 0b666d1c629e84493c80175d497f6f723b74111b35162ae28381c3dc1e422883
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
